Organon (OGN) Acquires TOFIDENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
April 1, 2025 7:30 AM EDTStrengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment
JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (Nasdaq: BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to... More
